ABSTRACT
References 510
The current conventional treatment of Alzheimer’s disease (AD) offers only modest symptomatic relief, which is not satisfactory considering the magnitude of the disease burden on patients and community as a whole. Several classes of pharmaceutical agents are currently used for the management of AD, among which cholinesterase inhibitors and glutamate receptor antagonists are suggested to produce the best clinical outcomes (Farlow et al., 2008).
